[3] Li H,Liu ZY,Wu N,et al. PARP inhibitor resistance:the underlying mechanisms and clinical implications[J]. Mol Cancer,2020,19(1):107. [4] Miller RE,Leary A,Scott CL,et al. ESMO recommendations on predictive biomarker testin...
近年来出现的聚腺苷二磷酸核糖聚合酶 [poly(ADP-ribose)polymerase,PARP] 抑制剂(PARP inhibitor,PARPi)为新型的靶向治疗药物之一,已经被应用于治疗包括乳腺癌在内的多种恶性肿瘤,并且已获得许多显著的效果,成为相关肿瘤研究的热点之一。 PARPi 的上市状况 PARPi 主要分为...
1.Bac Viet Le, Paulina Podszywałow-Bartnicka, Katarzyna Piwocka, and Tomasz Skorski, Pre-Existing and Acquired Resistance to PARP Inhibitor-Induced Synthetic Lethality, Cancers 2022, 14, 5795. 2.Quigley, D.; Alumkal, J.J.; Wyatt, A.W.; Kothari, V.; Foye, A.; Lloyd, P.; Aggar...
同源重组缺陷(Homologous Recombination Deficiency, HRD)是DNA修复途径缺陷的结果,会造成基因组和染色体的不稳定。HRD阳性常见于卵巢癌患者中,是卵巢癌聚腺苷二磷酸核糖聚合酶抑制剂(PARP inhibitor, PARPi)治疗相关的重要生物标志物之一。 在初诊晚期卵巢癌患者中,HRD检测对于患者使用PARPi一线(1L)维持治疗疗效的预测价...
英文名：Nicotinamide； PARP inhibitor;3 Pyridinecarboxamide;3-Pyridinecarboxamide;B 3, VitaminB3； Vitamin PP;CAS号：98-92-0 结构式：c1cc(cnc1)C(=N)O 分子式：C6H6N2O 分子量：122.12 闪点：150 °C 熔点：128-131°C 沸点：257.7±32.0 °C at 760 mmHg 极化度：13.3±0.5 10-24cm3 密...
[15].Wang L, Yang C, Xie C, et al. Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials. Cancer Sci. 2019;110(3):1064-1075. doi:10.1111/cas.13947 [16].Li N, Bu H, Liu J, et al. An Open-label, Multicenter, Single...
INO-1001 is a novel PARP inhibitor, known to sensitize cells to radiation in vitro by inhibiting the repair of DNA damage. 温馨提示:INO-1001,品质稳定,纯度>98+%,仅供实验使用.产品质量严格控制,保证品质。 关键字:INO-1001,INO1001 公司简介 ...
1.Bac Viet Le, Paulina Podszywałow-Bartnicka, Katarzyna Piwocka, and Tomasz Skorski, Pre-Existing and Acquired Resistance to PARP Inhibitor-Induced Synthetic Lethality, Cancers 2022, 14, 5795. 2.Quigley, D.; Alumkal, J.J.; Wyatt,A.W.; Kothari, V.; Foye, A.; Lloyd, P.; Aggarwa...
2.ESMO: PARP inhibitor plus immunotherapy lowers risk of endometrial cancer progression over chemotherapy alone https://www.mdanderson.org/newsroom/esmo-parp-inhibitor-plus-immunotherapy-lowers-risk-of-endometrial-cancer-progression-over-chemotherapy-alone.h00-159622590.html...
《TherapeuticPotential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors》刊登于Frontiers in Oncology肿瘤学前沿杂志中,详述阐明了PARP抑制和免疫联合治疗在改善实体肿瘤患者预后方面的前景,总结早期研究成果并展望进行中的研究,下面就由小编来为大家解读一下这篇文章。